BACKGROUND: Current guidelines recommend that clopidogrel should be held for 5 days prior to coronary artery bypass graft (CABG) procedure. However, it is unknown if this recommendation should apply to robotic-assisted (rCABG), which is less invasive because it does not involve sternotomy and thus reduces the risk of bleeding. OBJECTIVE: To compare postoperative bleeding for rCABG patients who were taking clopidogrel within 5 days of the procedure with those who were not taking clopidogrel. METHODS: This was a retrospective cohort study conducted between January 1, 2012 and December 31, 2012 of consecutive patients undergoing rCABG. Patients were categorized into 2 groups based on whether or not clopidogrel was administered within 5 days prior to the date of surgery. The primary outcome measure was the occurrence of the Bleeding Academic Research Consortium (BARC) definition for CABG-related bleeding. The secondary outcome measure was a comparison of chest tube output during the first 24-hour postoperative period. RESULTS: A total of 136 rCABG patients were included in the final analyses. Of these, 39 (29%) received clopidogrel within 5 days of surgery. CABG-related bleeding using the BARC definition occurred in 26% of patients who received clopidogrel and 8% of patients who did not (P = .011). Median chest tube output during the first 24-hour postoperative period was also greater in patients who received clopidogrel (900 vs 735 mL, P = .002). CONCLUSIONS: The use of clopidogrel within 5 days of rCABG is associated with greater postoperative bleeding and chest tube output, as defined by the BARC criteria.
BACKGROUND: Current guidelines recommend that clopidogrel should be held for 5 days prior to coronary artery bypass graft (CABG) procedure. However, it is unknown if this recommendation should apply to robotic-assisted (rCABG), which is less invasive because it does not involve sternotomy and thus reduces the risk of bleeding. OBJECTIVE: To compare postoperative bleeding for rCABGpatients who were taking clopidogrel within 5 days of the procedure with those who were not taking clopidogrel. METHODS: This was a retrospective cohort study conducted between January 1, 2012 and December 31, 2012 of consecutive patients undergoing rCABG. Patients were categorized into 2 groups based on whether or not clopidogrel was administered within 5 days prior to the date of surgery. The primary outcome measure was the occurrence of the Bleeding Academic Research Consortium (BARC) definition for CABG-related bleeding. The secondary outcome measure was a comparison of chest tube output during the first 24-hour postoperative period. RESULTS: A total of 136 rCABGpatients were included in the final analyses. Of these, 39 (29%) received clopidogrel within 5 days of surgery. CABG-related bleeding using the BARC definition occurred in 26% of patients who received clopidogrel and 8% of patients who did not (P = .011). Median chest tube output during the first 24-hour postoperative period was also greater in patients who received clopidogrel (900 vs 735 mL, P = .002). CONCLUSIONS: The use of clopidogrel within 5 days of rCABG is associated with greater postoperative bleeding and chest tube output, as defined by the BARC criteria.
Authors: Kim A Eagle; Robert A Guyton; Ravin Davidoff; Fred H Edwards; Gordon A Ewy; Timothy J Gardner; James C Hart; Howard C Herrmann; L David Hillis; Adolph M Hutter; Bruce Whitney Lytle; Robert A Marlow; William C Nugent; Thomas A Orszulak Journal: Circulation Date: 2004-10-05 Impact factor: 29.690
Authors: Kevin A Bybee; Brian D Powell; Uma Valeti; A Gabriela Rosales; Stephen L Kopecky; Charles Mullany; R Scott Wright Journal: Circulation Date: 2005-08-30 Impact factor: 29.690
Authors: Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White Journal: Circulation Date: 2011-06-14 Impact factor: 29.690
Authors: L J Dacey; J J Munoz; E R Johnson; B J Leavitt; C T Maloney; J R Morton; E M Olmstead; J D Birkmeyer; G T O'Connor Journal: Ann Thorac Surg Date: 2000-12 Impact factor: 4.330
Authors: Ludhmila A Hajjar; Jean-Louis Vincent; Filomena R B G Galas; Rosana E Nakamura; Carolina M P Silva; Marilia H Santos; Julia Fukushima; Roberto Kalil Filho; Denise B Sierra; Neuza H Lopes; Thais Mauad; Aretusa C Roquim; Marcia R Sundin; Wanderson C Leão; Juliano P Almeida; Pablo M Pomerantzeff; Luis O Dallan; Fabio B Jatene; Noedir A G Stolf; Jose O C Auler Journal: JAMA Date: 2010-10-13 Impact factor: 56.272
Authors: Marc S Sabatine; Christopher P Cannon; C Michael Gibson; Jose L López-Sendón; Gilles Montalescot; Pierre Theroux; Marc J Claeys; Frank Cools; Karen A Hill; Allan M Skene; Carolyn H McCabe; Eugene Braunwald Journal: N Engl J Med Date: 2005-03-09 Impact factor: 91.245
Authors: Jeffrey S Berger; Carla B Frye; Qing Harshaw; Fred H Edwards; Steven R Steinhubl; Richard C Becker Journal: J Am Coll Cardiol Date: 2008-11-18 Impact factor: 24.094
Authors: Christopher Cao; Praveen Indraratna; Mathew Doyle; David H Tian; Kevin Liou; Stine Munkholm-Larsen; Ciska Uys; Sohaib Virk Journal: Ann Cardiothorac Surg Date: 2016-11